Frederic Moulin

Frederic Moulin

Auto-generated profile, based on publicly available information

Frederic Moulin

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
DDDavid C. Dorman
David C. Dorman
FMFrederic J.-M. Moulin
Frederic J.-M. Moulin
BMBrian E. McManus
Brian E. McManus
KMKristen C. Mahle
Kristen C. Mahle
RJR. Arden James
R. Arden James
MFMelanie Foster
Melanie Foster
Hydrogen sulfide (H2S) is an important brain, lung, and nose toxicant. Inhibition of cytochrome oxidase is the primary biochemical effect associated with lethal H2S exposure. The objective of this study was to evaluate the relationship between the concentration of sulfide and cytochrome oxidase activity in target tissues following acute exposure to sublethal concentrations of inhaled H2S. Hindbrain, lung, liver, and nasal (olfactory and respiratory epithelial) cytochrome oxidase activity and sulfide concentrations were determined in adult male CD rats immediately after a 3-h exposure to H2S (10, 30, 80, 200, and 400 ppm). We also determined lung sulfide and sulfide metabolite concentrations at 0, 1.5, 3, 3.25, 3.5, 4, 5, and 7 h after the start of a 3-h H2S exposure to 400 ppm. Lung sulfide concentrations increased during H2S exposure and rapidly returned to endogenous levels within 15 min after the cessation of the 400-ppm exposure. Lung sulfide metabolite concentrations were transiently increased immediately after the end of the 3-h H2S exposure. Decreased cytochrome oxidase activity was observed in the olfactory epithelium following exposure to ≥ 30 ppm H2S. Increased olfactory epithelial sulfide concentrations were observed following exposure to 400 ppm H2S. Hindbrain and nasal respiratory epithelial sulfide concentrations were unaffected by acute H2S exposure. Nasal respiratory epithelial cytochrome oxidase activity was reduced following acute exposure to ≥ 30 ppm H2S. Liver sulfide concentrations were increased following exposure to ≥ 200 ppm H2S and cytochrome oxidase activity was increased following inhalation exposure to ≥ 10 ppm H2S. Our results suggest that cytochrome oxidase inhibition is a sensitive biomarker of H2S exposure in target tissues, and sulfide concentrations are unlikely to increase postexposure in the brain, lung, or nose following a single 3-h exposure to ≤ 30 ppm H2S.

1 January 2005 in Toxicologic Pathology
Verified
Journal Article
Open access
DDDonna M. Dambach
Donna M. Dambach
BABarbara A. Andrews
Barbara A. Andrews
FMFrederic Moulin
Frederic Moulin
Hepatotoxicity remains a significant cause for drug failures during clinical trials. This is due, in part, to the idiosyncratic nature of toxicity in humans and inherent physiological differences between humans and preclinical species leading to limited correct prediction of adverse responses in humans. To address this issue, robust screening assays are being developed, which have heightened predictive capacity for human hepatotoxicity, and may be utilized throughout the discovery and development phases in conjunction with traditional in vivo methods, for decision making during drug selection and risk assessment. This manuscript describes an example application of in vitro-based strategies using human hepatocyte cultures in lead optimization screening in conjunction with ADME profiling, for evaluation of compound-associated CYP450 induction potential, and the identification of potentially useful biomarkers as predictors of hepatotoxicity for use in vitro, and in preclinical species and humans.

5 September 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FAFranck Atienzar
Franck Atienzar
EBEric A. Blomme
Eric A. Blomme
Minjun ChenMinjun Chen
Minjun Chen
PHPhilip Hewitt
Philip Hewitt
JKJ. Gerry Kenna
J. Gerry Kenna
DDDonna M. Dambach
Donna M. Dambach
Drug-induced liver injury (DILI) is a major cause of late-stage clinical drug attrition, market withdrawal, black-box warnings, and acute liver failure. Consequently, it has been an area of focus for toxicologists and clinicians for several decades. In spite of considerable efforts, limited improvements in DILI prediction have been made and efforts to improve existing preclinical models or develop new test systems remain a high priority. While prediction of intrinsic DILI has improved, identifying compounds with a risk for idiosyncratic DILI (iDILI) remains extremely challenging because of the lack of a clear mechanistic understanding and the multifactorial pathogenesis of idiosyncratic drug reactions. Well-defined clinical diagnostic criteria and risk factors are also missing. This paper summarizes key data interpretation challenges, practical considerations, model limitations, and the need for an integrated risk assessment. As demonstrated through selected initiatives to address other types of toxicities, opportunities exist however for improvement, especially through better concerted efforts at harmonization of current, emerging and novel in vitro systems or through the establishment of strategies for implementation of preclinical DILI models across the pharmaceutical industry. Perspectives on the incorporation of newer technologies and the value of precompetitive consortia to identify useful practices are also discussed.

4 November 2015 in Nature
Verified
Journal Article
Closed access
PDF file
JSJin-Hua Sun
Jin-Hua Sun
DIDonald R. O’boyle Ii
Donald R. O’boyle Ii
RFRobert A. Fridell
Robert A. Fridell
DLDavid R. Langley
David R. Langley
CWChunfu Wang
Chunfu Wang
MGMin Gao
Min Gao

31 August 2004 in Toxicology in Vitro
Verified
Journal Article
Closed access
JGJi Gao
Ji Gao
LGLeah Ann Garulacan
Leah Ann Garulacan
SSStephen M Storm
Stephen M Storm
SHStanley A Hefta
Stanley A Hefta
GOGregory J Opiteck
Gregory J Opiteck
DDDonna M Dambach
Donna M Dambach

21 August 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PDPratik Devasthale
Pratik Devasthale
YWYing Wang
Ying Wang
WWWei Wang
Wei Wang
JFJohn Fevig
John Fevig
JFJianXin Feng
JianXin Feng
LHLawrence G. Hamann
Lawrence G. Hamann